Prostate cancer clinical trials consortium: dana-farber
Active Project Grant Awarded Last action
- Award ID
- HT9425261E163
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,000,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 3% complete
- Place of performance
- Boston, MA 02215, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield and clinical applications. Awards under this program typically range from $100,000 to $20 million and carry performance periods averaging three to four years.
Quick answers
Who received award HT9425261E163?
HT9425261E163 was awarded to Dana-Farber Cancer Institute, Inc. by Defense Health Agency (Department of Defense) on September 30, 2026.
How much is award HT9425261E163 worth?
$2,000,000 has been obligated on HT9425261E163.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award